The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.

Overview: Pfizer stock is trading near $25.86 with moderate upside potential based on the forecast range of up to ...

If you are wondering whether Pfizer's current share price reflects its underlying value, you are not alone. This article will ...

Pfizer PFE faces patent expirations amounting to more than one quarter of 2024 revenue by 2028, and the 2023 acquisition of oncology-focused biotech Seagen boosted the firm’s invested capital base, ...

Pfizer Inc. (NYSE:PFE) is included among Dividend Contenders List: Top 20 Stocks. Reuters reported on January 20 that Britain ...

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum ...

Is Back on Investors’ Radar Pfizer (PFE) is attracting fresh attention after a period of mixed share performance, with the ...

Pfizer stock is a deep-value kind of blue chip with a yield of more than 7%. The dividend looks safe — for now. The real question is whether there’s enough growth and innovation in the pipeline as the ...

Pfizer’s PFE third-quarter revenue fell 6%, as acquisition charges outweighed cost efficiencies and pushed adjusted diluted EPS down 18%. In the battle for Metsera’s obesity pipeline, Pfizer announced ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Pfizer is steering much of its pandemic revenue into oncology, as Chief Executive Albert ...